The Business of Biofabrication

Tiger Aesthetics Medical, a division of Tiger Biosciences, has announced a strategic investment in GenesisTissue Inc., a biotechnology company developing 3D bioprinted scaffolds for breast reconstruction and cosmetic surgery. The partnership aims to accelerate the development of regenerative tissue solutions intended to provide natural, long-term alternatives to traditional implants.

Investment Overview

The collaboration builds on Tiger Aesthetics’ expanding focus on tissue engineering and regenerative medicine. Earlier in 2025, the company introduced alloClae, a structural adipose tissue graft designed for body contouring procedures. The investment in GenesisTissue represents an extension of this strategy, combining biologically derived materials with emerging manufacturing technologies.

“GenesisTissue shares our vision of advancing regenerative options in aesthetic and reconstructive surgery,” said Caro Van Hove, President of Tiger Aesthetics. “Its 3D bioprinted scaffold technology complements our existing product lines and supports the broader goal of developing treatments that integrate naturally with the human body.”

Technology Focus

GenesisTissue is developing a personalized, degradable scaffold designed to provide mechanical support for autologous or allogeneic fat transfer in breast reconstruction. The scaffold is intended to gradually degrade as the patient’s own tissue replaces it, potentially offering a pathway toward fully natural restoration.

According to Katie Weimer, CEO and co-founder of GenesisTissue, advances in 3D bioprinting and biomaterials are creating new opportunities to move beyond conventional silicone implants. “We see a future where technology and biology come together to restore form and function through regenerative approaches,” she said.

The company’s technology platform integrates digital surgical planning, advanced biomaterials, and precision bioprinting. It is being developed for applications following lumpectomy and mastectomy, as well as for elective cosmetic procedures. All products remain investigational and have not yet been cleared by the U.S. Food and Drug Administration (FDA).

Market Context

Globally, more than two million women are diagnosed with breast cancer each year. In the United States, approximately 200,000 undergo mastectomy or lumpectomy procedures, with many opting out of reconstruction due to the limitations of implant-based solutions. Tissue-engineered scaffolds and biointegrative materials are being explored as potential methods to address these gaps in reconstructive options.

Company Backgrounds

Tiger Aesthetics Medical, LLC, headquartered in Conshohocken, Pennsylvania, develops regenerative and aesthetic products across a broad portfolio that includes structural adipose tissue grafts, silicone implants, expanders, and fat transfer systems. The company is part of Tiger Biosciences, which focuses on human cell and tissue processing technologies.
www.tiger-aesthetics.com

GenesisTissue Inc., headquartered in Colorado, is an early-stage biotechnology company working to apply 3D bioprinting and biomaterial design to breast reconstruction and cosmetic surgery. Its mission centers on developing living, regenerative alternatives to synthetic implants through personalized, patient-specific tissue scaffolds.